- Home
- EXP vs LEGN Comparison
EXP vs LEGN Comparison
Compare EXP & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXP | LEGN |
|---|---|---|
| Founded | 1963 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 5.9B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EXP | LEGN |
|---|---|---|
| Price | $227.25 | $22.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $252.22 | $69.67 |
| AVG Volume (30 Days) | 366.2K | ★ 2.5M |
| Earning Date | 01-28-2026 | 11-12-2025 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 13.52 | N/A |
| Revenue | ★ $2,301,796,000.00 | $909,045,000.00 |
| Revenue This Year | $2.81 | $68.83 |
| Revenue Next Year | $3.96 | $51.27 |
| P/E Ratio | $16.65 | ★ N/A |
| Revenue Growth | 1.50 | ★ 74.75 |
| 52 Week Low | $191.91 | $22.28 |
| 52 Week High | $283.00 | $45.30 |
Technical Indicators
Market Signals| Indicator | EXP | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.38 | 21.96 |
| Support Level | $216.14 | $26.43 |
| Resistance Level | $229.48 | $28.97 |
| Average True Range (ATR) | 4.98 | 1.57 |
| MACD | 1.55 | -0.43 |
| Stochastic Oscillator | 89.60 | 0.91 |
Price Performance
Historical ComparisonAbout EXP Eagle Materials Inc
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.